Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

Hae Won Yoo, Jun Yong Park, Sang Gyune Kim, Young Kul Jung, Sae Hwan Lee, Moon Young Kim, Dae Won Jun, Jae Young Jang, Jin Woo Lee, Oh Sang Kwon

Research output: Contribution to journalArticlepeer-review

Abstract

We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN. Clinical trials registration: ClinicalTrials.gov (NCT02865369).

Original languageEnglish
Article number193
JournalScientific reports
Volume12
Issue number1
DOIs
Publication statusPublished - 2022 Dec

Bibliographical note

Funding Information:
This work was supported by the SoonChunHyang University Research Fund and BMS (Bristol-Myers Squibb).

Publisher Copyright:
© 2022, The Author(s).

All Science Journal Classification (ASJC) codes

  • General

Fingerprint

Dive into the research topics of 'Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents'. Together they form a unique fingerprint.

Cite this